Letrozole Dose Increments in PCOS Patients Resistant to Letrozole Ovulation Induction
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- ovulation rate
研究概览
简要总结
Objectives: To study the effect of Letrozole dose increments on ovulation rate and endometrial thickness as a primary outcomes in patients with polycystic ovary syndrome who previously resistant to letrazole conventional dose, and chemical and clinical pregnancy considered as secondary outcomes.
详细描述
A prospective cohort clinical trial study will be carried out at Beni Suef outpatient clinic from the period of October 2023 till January 2024, on 102 PCOS patients who received Letrozole for one month showing resistance or anovulation.
Inclusion criteria: Age 18 - 40 years old, normal semen analysis of their male partner, and diagnosis of PCOS based on a modified form of the Rotterdam criteria (at least two of the mentioned three criteria: chronic anovulation oligomenorrhea, clinical or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound).
Exclusion criteria: Any contraindications for pregnancy, and patients received other medications for ovulation induction such as metformin or clomiphene citrate and gonadotropins concomitantly, hyperprolactinemia; abnormal thyroid functions; multiple uterine fibroids; suspicion of endometriosis and adenomyosis The study performed on 102 PCOS patients resistant to conventional regimen for Letrozole, they were divided into 2 groups, Group A(received Femara 2.5 mg (Novartis pharma ) 3 tablets per day starting from the second day of the menstrual cycle for 5 days ) and Group B : received femara 2.5 mg (2 tablets twice daily for 5 days starting from the second day of the cycle. Transvaginal ultrasound for tracking follicular growth and endometrial thickness performed on 12th and 14th day of the cycle. Primary outcomes of the study were the follicular size and endometrial thickness (ovulation detection). Secondary outcomes were the biochemical and clinical pregnancy rates.
Ethical considerations Approval by the institution ethical committee, The Beni-Suef University Faculty of Medicine Research Ethics Committee has approved the study (FMBSUREC/03102023/Ali). Individual consent process: informed consent was taken after explaining the study objectives and procedures to each patient.
Sample size was calculated using G*power (8) for sample size calculation, based on assumption that effect size was 0.5. For a confidence 95% and power 80%, and assumption for using a t-test for two independent means groups, the minimum required sample size is 102 participants with 51 participants in each group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •normal semen analysis of their male partner
- •Diagnosis of PCOS based on a modified form of the Rotterdam criteria
排除标准
- •Any contraindications for pregnancy
- •patients received other medications for ovulation induction such as metformin or clomiphene citrate and gonadotropins concomitantly
- •hyperprolactinemia
- •abnormal thyroid functions
- •multiple uterine fibroids
研究组 & 干预措施
femara 1x3
Femara 2.5 mg (Novartis pharma ) 3 tablets per day starting from the second day of the menstrual cycle for 5 days
干预措施: Letrozole 2.5mg (Drug)
femara 2x2
(Femara 2.5 mg (Novartis pharma )2 tablets twice daily for 5 days starting from the second day of the cycle
干预措施: Letrozole 2.5mg (Drug)
结局指标
主要结局
ovulation rate
时间窗: 1 month
the follicular size by trans-vaginal ultrasound reached more than 18 mm
endometrial thickness
时间窗: 1 cycle (1month)
assessed by trans-vaginal ultrasound
次要结局
- pregnancy rate(1 month)
研究者
Sara Abdallah Mohamed Salem
Lecturer of Gynecology and obstetrics Faculty of medicine Beni-Suef University
Beni-Suef University
